N-[(toluene-4-sulfonyl)-(3-chloro-4,5-dimethoxyphenyl)methyl]formamide | 1245716-01-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: N-[(toluene-4-sulfonyl)-(3-chloro-4,5-dimethoxyphenyl)methyl]formamide
• 英文别名: N-[(3-chloro-4,5-dimethoxyphenyl)-(4-methylphenyl)sulfonylmethyl]formamide
• CAS: 1245716-01-1
• 化学式: C₁₇H₁₈ClNO₅S
• 分子量: 383.853
• InChiKey: IGBOBZMZZPADEI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  25
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  90.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  N-[(toluene-4-sulfonyl)-(3-chloro-4,5-dimethoxyphenyl)methyl]formamide 在 溶剂黄146 、 三乙胺 、 三氯氧磷 作用下， 以 乙二醇二甲醚 、 乙醇 为溶剂， 反应 7.0h， 生成 1-methyl-4-(3-chloro-4,5-dimethoxyphenyl)-5-(3-fluoro-4-ethoxyphenyl)imidazole
  参考文献：
  名称：

  [EN] COMBRETASTATIN ANALOGS FOR USE IN THE TREATMENT OF CANCER
  [FR] ANALOGUES DE LA COMBRÉTASTATINE POUR UTILISATION DANS LE TRAITEMENT DU CANCER

  摘要：

  本发明涉及康柏替斯汀的特定类似物，特别是本文所描述和定义的式(I)化合物，以及包含这些化合物的药物组合物，以及它们的医疗用途，特别是在治疗或预防癌症，包括多药耐药癌症方面。

  公开号：

  WO2011138409A1
• 作为产物：
  描述：

  3-氯-4,5-二甲氧基苯(甲)醛 、 对甲苯磺酸 、 formamide 在 camphor-10-sulfonic acid 作用下， 反应 16.0h， 以51%的产率得到N-[(toluene-4-sulfonyl)-(3-chloro-4,5-dimethoxyphenyl)methyl]formamide
  参考文献：
  名称：

  [EN] COMBRETASTATIN ANALOGS FOR USE IN THE TREATMENT OF CANCER
  [FR] ANALOGUES DE LA COMBRÉTASTATINE POUR UTILISATION DANS LE TRAITEMENT DU CANCER

  摘要：

  本发明涉及康柏替斯汀的特定类似物，特别是本文所描述和定义的式(I)化合物，以及包含这些化合物的药物组合物，以及它们的医疗用途，特别是在治疗或预防癌症，包括多药耐药癌症方面。

  公开号：

  WO2011138409A1

文献信息

• COMBRETASTATIN ANALOGS FOR USE IN THE TREATMENT OF CANCER
  申请人：Schobert Rainer

  公开号：US20130137740A1

  公开（公告）日：2013-05-30

  The present invention relates to specific analogs of combretastatin, in particular the compounds of formula (I) as described and defined herein, and pharmaceutical compositions comprising the compounds, as well as their medical use, in particular in the treatment or prevention of cancer, including multidrug-resistant cancer.

  本发明涉及康布雷塔斯汀的特定类似物，特别是公式（I）中所描述和定义的化合物，以及包含这些化合物的药物组成物，以及它们的医疗用途，特别是在治疗或预防癌症，包括多药耐药性癌症方面的应用。
• Combretastatin analogs for use in the treatment of cancer
  申请人：Schobert Rainer

  公开号：US08980933B2

  公开（公告）日：2015-03-17

  The present invention relates to specific analogs of combretastatin, in particular the compounds of formula (I) as described and defined herein, and pharmaceutical compositions comprising the compounds, as well as their medical use, in particular in the treatment or prevention of cancer, including multidrug-resistant cancer.

  本发明涉及柯布雷他汀的特定类似物，特别是公式(I)中所描述和定义的化合物，以及包含这些化合物的药物组合物，以及它们的医疗用途，特别是在治疗或预防癌症，包括多药耐药癌症方面的应用。
• 4-(3-Halo/amino-4,5-dimethoxyphenyl)-5-aryloxazoles and -<i>N</i>-methylimidazoles That Are Cytotoxic against Combretastatin A Resistant Tumor Cells and Vascular Disrupting in a Cisplatin Resistant Germ Cell Tumor Model
  作者：Rainer Schobert、Bernhard Biersack、Andrea Dietrich、Katharina Effenberger、Sebastian Knauer、Thomas Mueller

  DOI：10.1021/jm100345r

  日期：2010.9.23

  New combretastatin A analogues featuring oxazole or N-methylimidazole bridged Z-alkenes and haloor amino-substituted A-rings were tested against various cancer cell lines and in testicular germ cell tumor xenografts in mice. Imidazoles with 3-halo-4,5-dimethoxy substituted A-rings and 3-amino-4-methoxy substituted B-rings (7b and 8b) were efficacious at nanomolar concentrations against cells of combretastatin A refractory HT-29 colon carcinoma, multidrug-resistant MCF-7/Topo breast carcinoma, and cisplatin-resistant 1411 HP testicular germ cell tumor. They induced apoptosis and inhibited tubulin polymerization. While well tolerated by mice at high doses, these imidazoles initiated extensive intratumoral hemorrhage and regressions of highly vascularized 1411 HP xenografts.
• Ru(η6-arene) complexes of combretastatin-analogous oxazoles with enhanced anti-tumoral impact
  作者：Bernhard Biersack、Katharina Effenberger、Sebastian Knauer、Matthias Ocker、Rainer Schobert

  DOI：10.1016/j.ejmech.2010.07.061

  日期：2010.11

  Oxazole-bridged combretastatin A-4 analogues bind to tubulin and exert anti-vascular and anti-angiogenic effects. When linked to Ru(eta(6)-arene) complex fragments, conjugates with additional cytotoxic activity result which can ruthenate bionucleophiles such as DNA and proteins. For instance, the Ru(11) (p-cymene)(isonicotinate)Cl-2 complex 6a of the known 4-(3,4,5-trimethoxyphenyl)-5-(3-hydroxy-4-methoxyphenyl)-oxazole 4a was far more active than the latter against cells of the p53-competent wild-type form of HCT-116 colon carcinoma at low 0.01 mu M concentrations. A fast reaction of 6a with nucleophilic N-acetyl-L-cysteine was observed in NMR studies. The Ru(arene) complexes 6a-c were also more efficacious against combretastatin-refractory p53(+) cells of human HT-29 colon carcinoma when compared to their parent 4-(3,4-dimethoxy-5-methoxy/halo-phenyl)-5-(3-hydroxy-4-methoxyphenyl)-oxazoles 4a-c. These cells are rich in ABC-transporters which are responsible for their multi-drug resistance and for which conjugates 6 are less good substrates than the phenols 4. Unlike 4a, its complex 6a also diminished the motility of human 518A2 melanoma cells in a wound-healing assay which is indicative of anti-metastatic activity in solid tumors. Overall, the Ru(arene) complex conjugates 6 broaden the anti-tumoral spectrum of the combretastatin A-4 analogues 4 considerably. (C) 2010 Elsevier Masson SAS. All rights reserved.
• US8980933B2
  申请人：——

  公开号：US8980933B2

  公开（公告）日：2015-03-17